Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
tasosartan
Known as:
5,8-dihydro-2,4-dimethyl-8-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)pyrido(2,3-d)pyrimidin-7(6H)-one
, taso-sartan
National Institutes of Health
Create Alert
Related topics
Related topics
3 relations
Broader (3)
Angiotensin II Type 1 Receptor Blockers
Pyrimidines
Tetrazoles
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
The role of gender relations in decision-making for access to antiretrovirals. A study of the AIDS Support Organisation (TASO) clients, Kampala district, Uganda
B. Bitangaro
2005
Corpus ID: 67939612
The way gender relations influen are and treatment particularly edicines is a challenge to HIV/AIDS programmes and to the…
Expand
Review
2001
Review
2001
Pharmacology of AT 1 -receptor Blockers
T. Unger
Blood pressure. Supplement
2001
Corpus ID: 45314205
Angiotensin II mediates its haemodynamic effects by binding to specific cell-surface receptors. In humans, two receptor subtypes…
Expand
2000
2000
Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding.
M. Maillard
,
J. Rossat
,
H. Brunner
,
M. Burnier
The Journal of pharmacology and experimental…
2000
Corpus ID: 22253521
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its…
Expand
Review
1999
Review
1999
Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics.
P. Timmermans
Hypertension research : official journal of the…
1999
Corpus ID: 9727638
Acceptance of the notion that physiologically specific interruption of the renin-angiotensin-aldosterone system (RAAS) is of…
Expand
Review
1999
Review
1999
Pharmacological properties of angiotensin II receptor antagonists.
P. Timmermans
The Canadian journal of cardiology
1999
Corpus ID: 24694991
The availability of selective, potent, orally active and long acting nonpeptide angiotensin II type 1 (AT1) receptor antagonists…
Expand
1999
1999
Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: Results from a 10-week, double-blind, placebo-controlled, dose-titration study
J. Neutel
,
V. Buckalew
,
S. Chrysant
,
W. Mroczek
,
D. Ruff
,
M. Weber
1999
Corpus ID: 73039357
Abstract Background Angiotensin II receptor antagonists are selective blockers of the renin-angiotensin system and represent an…
Expand
1999
1999
The angiotensin AT(1) receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling.
J. Hines
,
S. Fluharty
,
R. Sakai
European journal of pharmacology
1999
Corpus ID: 41354529
The angiotensin II type 1 (AT(1)) receptor plays a pivotal role in the regulation of blood pressure and electrolyte balance, and…
Expand
1998
1998
Metabolites of the angiotensin II antagonist tasosartan: the importance of a second acidic group.
J. Ellingboe
,
M. Collini
,
+8 authors
J. Bagli
Journal of medicinal chemistry
1998
Corpus ID: 20725718
Described in this paper is the synthesis and pharmacological activity of five metabolites of the angiotensin II antagonist…
Expand
1998
1998
Effects of angiotensin antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients
C. Rhéaume
,
P. Waib
,
Y. Lacourciére
,
J. Cléroux
Journal of hypertension
1998
Corpus ID: 9043650
Objective Evaluate the effects of 2 weeks of treatment with tasosartan (1) on cardiac function at rest and during submaximal…
Expand
1998
1998
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial of Four Doses of Tasosartan in Patients With Essential Hypertension
Y. Lacourciére
,
J. Pool
,
+4 authors
W. B. Smith
1998
Corpus ID: 59544894
Tasosartan, a new, long-act ing, nonpeptide angiotensin II receptor antagonist was evaluated in a randomized, double-blind…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE